Donanemab for Alzheimer's Disease

This trial focuses on determining whether annual doses of donanemab, a treatment for Alzheimer's disease, offer ongoing benefits for participants who have previously used it. Participants will receive either donanemab or a placebo (a treatment with no active drug) to compare results. This study may suit those who have completed a specific previous study with donanemab and have a reliable partner familiar with their daily activities and cognitive abilities. As a Phase 3 trial, it represents the final step before potential FDA approval, providing participants an opportunity to contribute to the validation of a promising treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Studies have shown that donanemab is generally well-tolerated in people with early Alzheimer's disease. Research found no significant issues compared to a placebo. However, some side effects have been reported, including ARIA (a type of brain swelling), headaches, and reactions to the infusion process.

The FDA approved donanemab in 2024 for mild cognitive impairment (early memory problems) and mild Alzheimer's disease, indicating that the drug met certain safety standards for these conditions. However, the FDA has raised concerns about the long-term safety of donanemab due to missing data from past studies.

Donanemab is unique because it targets amyloid plaques in the brain, which are thought to be a key factor in Alzheimer's disease progression. Most current treatments, like donepezil and memantine, focus on managing symptoms rather than altering the disease's course. Donanemab uses an antibody to specifically remove these plaques, potentially slowing down or modifying disease progression, which is why researchers are so excited about its potential impact.

Research has shown that donanemab can significantly slow the progression of Alzheimer's disease, particularly in its early stages. In this trial, participants will receive either donanemab or a placebo. Studies have found that individuals taking donanemab experienced a slower decline in memory and daily functioning compared to those on a placebo. For instance, one study found a 32% slower decline in those treated with donanemab. Another study demonstrated that donanemab slowed Alzheimer's progression by 22% in patients with early symptoms. These findings suggest that donanemab might help people with Alzheimer's maintain their daily activities for a longer time.⁴⁶⁷⁸⁹